Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically-engineered autologous T cell therapy with chimeric antigen receptors.

According to the Complaint, on August 27, 2017, Kite Pharma’s Board of Directors caused the Company to enter into an agreement and plan of merger with Gilead.

On September 5, 2017, Defendants filed a Solicitation/Recommendation Statement (the “Solicitation Statement”) with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

This case was voluntarily dismissed on November 15, 2017.